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Background
Pseudomonas aeruginosa infection is seldom eradicated in patients with cystic fibrosis despite intensive antipseudomonal treatment. Upper airway sites of infection may contribute to perpetuation of lower airways infection. This study was designed to find out which extrapulmonary sites are infected and whether the strains at these sites are identical to those in the lungs. Methods Sputum and upper airway samples from 42 patients were cultured for P aeruginosa and stool samples from 20 patients were also tested. Nineteen isolates from sputum and extrapulmonary sites from four patients were genotyped with the pCM tox probe. Results P aeruginosa was isolated from the sputum of 36 patients, 34 of whom had infection in the upper airways. Six of the 20 patients tested were positive for P aeruginosa in the stool. The nasopharynx was colonised in 30 patients, the oropharynx in 29, the middle meatus in 13, the external nares in six, and the inferior turbinate in four. Three of four patients tested had the same strain of P aeruginosa ( These may act as sanctuary sites for P aeruginosa as effective antimicrobial concentrations may not be reached here. 4 Such reservoirs might reseed the lungs and perpetuate infection. If P aeruginosa is harboured outside the lungs accurate identification of the strain in each patient is required if a relation between extrapulmonary sites and the lungs is to be supported.
We assessed the upper airways clinically, and examined the frequency of colonisation of extrapulmonary sites by P aeruginosa in a cross sectional study of adults with cystic fibrosis. Extrapulmonary isolates were compared with pulmonary strains by genotyping.
Methods
Forty two patients with cystic fibrosis (23 female; mean age 26 (range 15-66) years) were selected randomly from outpatients. They were asked about current symptoms of nasal obstruction and sinus infection before anterior and posterior rhinoscopy. The presence of nasal polyps, mucus strands, and nasal mucosal hyperaemia was noted. Forced expiratory volume in one second (FEVI) was expressed as a percentage of the predicted value.5 Sputum was collected after physiotherapy and dry swabs were taken from the inferior turbinate, external nares, middle meatus, oropharynx (tonsillar fossa), and nasopharynx (postnasal space); samples were taken from the middle meatus because the paranasal sinuses drain into this region. Stool samples were returned by 20 patients within 48 hours of the outpatient visit. In 21 patients the upper airways were sampled twice during the nine month study. Twenty seven patients were regularly taking nebulised antipseudomonal antibiotics by mouthpiece.
BACTERIOLOGICAL METHODS
Sputum was homogenised after dilution with an equal volume of Ringer's solution and then plated (0 1 ml) on to Pseudomonas Isolation Agar (PIA: Difco Laboratories, Detroit, Michigan). Upper airway swabs were plated immediately on to King's A agar.6 Stools were enriched in acetamide broth7 and inoculated similarly. After aerobic incubation at 37°C for 48 hours isolates that produced the characteristic pigment pyocyanin were accepted as P aeruginosa. Non-pigmented isolates were identified by the API 20NE system (BioMerieux Ltd, Basingstoke). figure) . The stool isolates from two of these patients were distinct from the airway strain.
Discussion
Our finding that most adults with cystic fibrosis who harbour P aeruginosa in the sputum also have their upper respiratory tract colonised make it clear that P aeruginosa has a proclivity for both the upper and the lower airways.
These results contrast with those of a recent study of children with cystic fibrosis,'2 where upper airway carriage of P aeruginosa correlated poorly with lower respiratory infection; this discrepancy may partly be due to age differences between the populations studied. The absence of upper airway symptoms or signs did not preclude colonisation by P aeruginosa at upper airway sites and most patients with upper airway infection were receiving regular nebulised antibiotics.
Identical strains were found in the upper and lower airways in three of the four patients whose strains were genotyped, thereby raising the possibility of a clinically important association between the sites. A prospective longitudinal study in children is required to determine the initial site of P aeruginosa colonisation in cystic fibrosis. Establishing this and targeting the primary site with antipseudomonal antimicrobials might help to determine whether the extrapulmonary sites are implicated in the initiation of pulmonary Upper airway positive and sputum culture negative for P aeruginosa 1
In two patients sputum culture was positive and upper airways negative for P aeruginosa and in five sputum culture was negative and upper airways negative for P aeruginosa. Meanwhile, to protect the donor lungs of transplant recipients with cystic fibrosis from acquiring P aeruginosa from the upper airways, we suggest that these sites are screened for P aeruginosa before operation and that any nasal obstruction is treated, so that delivery of nebulised agents by face mask is facilitated.
The effect of P aeruginosa in the gut on pulmonary infection has not been fully investigated. Recurrent aspiration of gastric contents might occur because of increased oesophageal reflux in patients with cystic fibrosis.'4 Studies of selective decontamination of the gut to protect against retrograde colonisation of the lungs are in progress.
Our finding of upper airway sites in which P aeruginosa may obtain sanctuary, persisting despite antimicrobial attack, highlights the need for evaluating the treatment of such reservoirs in patients with cystic fibrosis at all stages of their disease. aeruginosa in adults with cystic fibrosis. 
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